We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

YHC:NASDAQLQR House Inc. Analysis

Data as of 2026-05-28 - not real-time

$0.85

Latest Price

8/10Risk

Risk Level: High

Executive Summary

LQR House Inc. (YHC) trades at $0.85, comfortably above the computed support of $0.69 but below the resistance near $1.05. The 20‑day SMA (0.91) sits just above the current price, while the 50‑day SMA (0.92) and 200‑day SMA (0.89) suggest a neutral trend. Technical momentum is weak, with a bearish MACD histogram and an RSI of 42 indicating limited upside momentum, and a 30‑day volatility of ~65% adds to short‑term price swings. Valuation multiples are unusually low – a trailing P/E of 2.8 and a P/B of 0.44 – yet the company’s fundamentals are fragile: revenue has plunged 64%, operating margin is –10%, and both operating and free cash flow are deeply negative. The recent strategic partnership with Hangzhou GSY Biotechnology could open a new functional‑beverage line, offering a potential catalyst, but the firm’s cash balance (~$6 M) barely cushions ongoing cash‑burn. Overall, the stock sits at a speculative sweet spot where cheap pricing meets high operational risk and elevated market volatility.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 4/10

Key Factors

  • Bearish MACD and neutral RSI suggest limited near‑term upside
  • Price remains above key support but volatility is ~65%
  • No dividend and thin trading volume increase short‑term uncertainty

Medium Term

1–3 years
Positive
Model confidence: 5/10

Key Factors

  • Strategic partnership with GSY biotech could unlock new revenue streams
  • Low valuation multiples (P/E 2.8, P/B 0.44) provide margin of safety
  • Improving market sentiment (Fear/Greed index in "Extreme Greed") may boost liquidity

Long Term

> 3 years
Cautious
Model confidence: 6/10

Key Factors

  • Sustained negative margins and cash‑flow deficits
  • High historical drawdown (~94%) and ongoing operational risk
  • Unclear path to profitability despite partnership announcements

Key Metrics & Analysis

Financial Health

Revenue Growth-64.20%
P/E Ratio2.8
ROE-177.15%
ROA-37.43%
Debt/Equity0.21
P/B Ratio0.4
Op. Cash Flow$-33817140
Free Cash Flow$-20728636

Technical Analysis

TrendNeutral
RSI41.8
Support$0.69
Resistance$1.05
MA 20$0.91
MA 50$0.92
MA 200$0.89
MACDBearish
VolumeIncreasing
Fear & Greed Index91.57

Valuation

GradeUndervalued
TypeValue

Risk Assessment

Beta0.99
Volatility64.88%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.